AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline ...

ICICI Securities is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 1570 in its research report dated August 19, 2025.

UChicago Medicine is launching a national cancer network to bring its academic medicine expertise to other communities in the ...

Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire -- Raised $3.6 million in registered direct offering in second quarter - REHOVOT ...

A large trial in a primary care setting found daily emollient use to be safe, feasible, and effective in reducing atopic ...

An announcement from Collplant Holdings ( ($CLGN) ) is now available. On August 20, 2025, CollPlant Biotechnologies reported its financial results ...

The Trump administration's ever-changing tariffs and Most Favored Nation drug pricing are part of a blizzard of unclear, ...